CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering

Dow Jones

2025/07/12

By Josh Beckerman

Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.

The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258.

The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor.

The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said.

Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow.

The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner.

Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 11, 2025 14:01 ET (18:01 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2550496379"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550496379\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550496379?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-12 02:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550496379","market":"other","top_or_hot":-1,"title":"CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n</p>\n<p>\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n</p>\n<p>\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n</p>\n<p>\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n</p>\n<p>\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n</p>\n<p>\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n</p>\n<p>\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 14:01 ET (18:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCEL-SCI Spikes After Saudi Arabia Drug-Filing Update, Stock Offering\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-07-12 02:01</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n</p>\n<p>\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n</p>\n<p>\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n</p>\n<p>\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n</p>\n<p>\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n</p>\n<p>\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n</p>\n<p>\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 11, 2025 14:01 ET (18:01 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CVM","symbol_name":"CEL-SCI Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550496379","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550496379","pubTimestamp":1752256860,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering.The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258.The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor.The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said.Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow.Later Friday, CEL-SCI said ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CVM":"CEL-SCI Corp","BK4139":"生物科技"},"translate_title":"沙特阿拉伯药物申报更新和股票发行后CEL-SCI飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CVM":0.9},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of CEL-SCI climbed after the company reported progress toward the filing of an application for multikine in Saudi Arabia, but pared their gains after it announced a stock offering. \n\n\n  The stock touched an intraday high of $7.09, but receded back to $3.98, up 4.2%, midday Friday. Volume was more than 25 million, compared with a 65-day average of 211,258. \n\n\n  The biotechnology company said earlier it reached an agreement with an undisclosed Saudi Arabian pharmaceutical and healthcare company for a partnership that spans regulatory and commercial activities for multikine, which is designed to help the immune system target a tumor. \n\n\n  The Saudi partner will file a Breakthrough Medicine Designation application in the coming weeks, CEL-SCI said. \n\n\n  Multikine is given after diagnosis and before surgery. CEL-SCI has reported favorable study results in patients with head and neck cancer, including pain reduction or cessation and improvement in ability to eat, drink and swallow. \n\n\n  The Vienna, Va., company said multiple Saudi Arabian funds have expressed interest in investing in the company or in its venture with the Saudi partner. \n\n\n  Later Friday, CEL-SCI said it is selling 1.5 million shares for $3.82 each. In May, the company closed a $5 million offering. It also had stock offerings in December and March. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 11, 2025 14:01 ET (18:01 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}